In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $123.02 per share. By comparison ...

The firm decreased its portfolio allocation in BIIB by 18.27% over the last quarter ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

The firm decreased its portfolio allocation in BIIB by 18.27% over the last quarter ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

During the last three months, 14 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, BIIB080. How Does the Fast Track Tag Benefit BIIB’s Drug Development?

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...

NASDAQ:BIIB opened at $122.98 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. Biogen Inc. has a one year low of $122.77 and a one year ...